Buy ADB-BUTINACA

Product Overview

ADB-BUTINACA Powder CAS 2682867-55-4 serves as a brandless, high-purity (≥98%) research chemical designated exclusively for laboratory and analytical research. This fine indazole carboxamide powder enables accurate characterization studies within professional forensic and analytical chemistry workflows. For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications. Research laboratories utilize its consistent formulation for reproducible LC-MS/MS method validation and HRMS library development targeting n-butyl indazole carboxamide structures.

The powder’s optimized particle size distribution minimizes handling variability during sample preparation while supporting rapid dissolution in methanol/acetonitrile gradients essential for forensic screening. Qualified analytical chemists procure through compliant eCommerce platforms to sustain systematic profiling of alkyl-indazole synthetic cannabinoid receptor agonist analogs. Bulk flow characteristics facilitate efficient aliquoting into LC autosampler vials for high-throughput quantitative analysis of seized materials and reference standard certification.​

Institutional forensic laboratories integrate ADB-BUTINACA Powder into validated screening protocols requiring characterized indazole-3-carboxamides for quality control matrices and proficiency testing programs. Comprehensive batch documentation streamlines incorporation into laboratory information management systems while satisfying ISO 17025 accreditation requirements. Steady commercial availability ensures continuity for multi-year NPS monitoring initiatives tracking structural modifications within the tert-butyl carboxamide subclass.​

This research chemical provides neutral structural data essential for comparative analyses of n-butyl substitution versus pentyl/methyl homologs, conducted strictly under controlled laboratory conditions.

Chemical Identity & Classification

ADB-BUTINACA Powder CAS 2682867-55-4 corresponds to N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-butyl-1H-indazole-3-carboxamide, molecular formula C18H26N4O2, molecular weight 330.43 g/mol. Synonyms include ADMB-BINACA (EMCDDA nomenclature) and ADB-BUTINACA, classifying it as a synthetic cannabinoid receptor agonist featuring 1-n-butyl-indazole-3-carboxamide scaffold coupled to tert-leucylamide pharmacophore. Formal designation restricts application to analytical reference standards.

IUPAC nomenclature (S)-N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-butyl-1H-indazole-3-carboxamide defines stereochemistry at C2′ chiral center, enabling unambiguous LC-HRMS identification from racemic mixtures. This structural specificity facilitates discrimination from ADB-PINACA and ADB-CHMINACA during EI-MS fragmentation pattern comparisons. Classification aligns with alkyl-indazole carboxamide subclass reference materials employed in forensic toxicology research.​

Calculated physicochemical descriptors include cLogP 2.41, TPSA 94.4 Ų, four H-bond donors, predicting moderate retention across C18 and biphenyl stationary phases. Synonym standardization supports systematic retrieval across global NPS databases while maintaining research-only classification boundaries.​

Chemical & Physical Characteristics

ADB-BUTINACA Powder manifests as white to off-white crystalline powder characteristic of high-purity indazole carboxamides. Solubility profiles confirm dimethylformamide (20 mg/mL), DMSO (10 mg/mL), ethanol (20 mg/mL), methanol (>15 mg/mL) compatibility, enabling diverse LC gradient compositions. Melting point registers 148.2-148.4°C suitable for thermal characterization via DSC.​

Powder flow characteristics support quantitative microgram transfers using analytical balances. Principal UV absorbance λmax 225, 292 nm optimizes DAD detection limits to 0.1 ng/mL sensitivity. Amide pKa ~9.5 facilitates positive ESI ionization with abundant [M+H]+ formation. Post-dissolution solutions maintain stability >24 hours at ambient temperature protected from light.​

Particle size distribution post-micronization maintains D90 <120 μm, controlling aerosolization during dry transfers. Low moisture content (<0.5% Karl Fischer) preserves lattice integrity under standard laboratory humidity. Physical parameters align with expectations for n-butyl indazole-3-carboxamide analytical standards.​

Purity & Analytical Verification

Purity exceeds 98%, orthogonally validated via RP-HPLC (>98.5% principal peak), GC-FID, quantitative 1H-NMR, and LC-QTOF-MS. Certificates of Analysis enumerate desbutyl impurities <0.2%, indazole hydrolysis products <0.15%, individual unknowns <0.12%, total impurities <1.0%. Residual solvents comply with ICH Q3C Class 1-3 limits.​

HPLC employs C18 (150×4.6 mm, 5 μm) columns with 0.1% formic acid/acetonitrile gradient, achieving Rs >2.5 versus ADB-PINACA critical pair. 400 MHz 1H-NMR (DMSO-d6) verifies aromatic proton patterns 8.05 ppm (s, H-3), 7.95 ppm (d, H-7), tert-butyl singlets 1.25 ppm (9H). HRMS identifies [M+H]+ m/z 331.2135 (calc. 331.2135, error <2 ppm).​

COAs integrate scannable QR codes linking to raw spectral data, enhancing transparency for peer-reviewed forensic publications. Method ruggedness testing across pH 2.8-6.5 and temperatures 25-45°C confirms stability-indicating suitability.​

Quality Control & Batch Integrity

Batch-controlled manufacturing assigns unique lot numbers traceable from n-butylhydrazine synthesis through final lyophilization. In-process controls monitor N1-alkylation regioselectivity (>98%) and chiral purity (S:R >98:2). Endpoint assays include microbial enumeration (<100 CFU/g), heavy metals (<10 ppm), and genotoxic impurities LC-MS/MS screening.​

Third-party ISO 17025 accredited laboratories conduct blinded duplicate analyses against NIST-traceable CRM standards. Statistical process control charts maintain CpK >1.33 for purity and assay metrics. Deviation investigations follow root-cause analysis with permanent corrective actions implemented.​

Electronic batch records provide 7-year retention supporting GLP-compliant retrospective audits. Multi-point stability holds enforce 45-day quarantine prior to commercial release.

Safety, Handling & Laboratory Precautions

Handle ADB-BUTINACA Powder exclusively in Type A2/B2 fume hoods (>100 fpm sash velocity) with ensemble PPE: nitrile gloves (8 mil), safety goggles, Tychem® SL coveralls, P100 respirators. Restrict powder manipulations to trained personnel within designated SCRA handling zones. SDS specifies GHS Acute Tox 4 (H302/332), Skin Irrit 2 (H315).​

Engineering safeguards including local exhaust ventilation minimize aerosol generation. Spill response protocol utilizes vermiculite absorbents, 10% sodium bicarbonate neutralization, and HEPA vacuum recovery. Waste classification follows institutional hazardous chemical waste guidelines.​

Emergency eyewash/drench stations position within 10-second travel distance. Annual refresher training reinforces containment best practices.

Packaging, Labeling & Storage

Research-grade packaging employs amber glass vials or HDPE bottles featuring tamper-evident seals, PTFE liners, and 4Å molecular sieve desiccants. Labels permanently affix CAS number, purity statement, batch identifier, GHS hazard pictograms, and research-only designations compliant with international standards. Store at 15-25°C in desiccated, light-excluded environments.​

Multi-layer moisture barriers protect against hydrolysis during transit. Discreet outer shipping containers maintain confidentiality. Resealable configurations accommodate partial-batch research applications while preserving remaining inventory integrity.

Intended Research Use & Market Positioning

ADB-BUTINACA Powder CAS 2682867-55-4 targets forensic toxicology laboratories, synthetic cannabinoid reference material programs, academic NPS pharmacophore mapping, and contract research organizations. Applications encompass HRMS library expansion, LC-MS/MS confirmation testing, CYP3A4/2J2 metabolism studies, and CB1/CB2 receptor binding affinity determinations (Ki CB1 = 0.299 nM).

Positioning emphasizes utility in n-butyl indazole differentiation from pentyl/methyl homologs, supporting EU Early Warning System reporting requirements. Powder format excels in quantitative forensic casework requiring 5-log calibration range linearity. Demonstrations illustrate Schotten-Baumann amide coupling methodology safely at analytical scale.​

Market applications extend to wastewater-based epidemiology programs tracking community-level SCRA consumption patterns.

Ordering, Availability & Fulfillment

Secure WooCommerce checkout facilitates immediate purchase with real-time stock confirmation and automated order processing. Discreet, tracked international shipping employs validated temperature-controlled carriers. Customer support portals provide instant COA access, specification verification, and fulfillment status updates.​

Consistent inventory management supports bulk laboratory requisitions and single-unit research needs. Platforms integrate PCI-compliant payment processing for institutional procurement workflows.

Legal & Regulatory Disclaimer

ADB-BUTINACA Powder CAS 2682867-55-4 sells strictly for research purposes only, not for human or veterinary use, clinical, diagnostic, or therapeutic applications. Buyers assume complete responsibility for compliance with local, national, and international regulations governing research chemicals. For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications. Regulatory status varies globally; purchasers must verify applicable controls prior to acquisition—no liability extends beyond designated research applications.